MX2023011498A - Toallita topica que contiene nifedipina y lidocaina. - Google Patents

Toallita topica que contiene nifedipina y lidocaina.

Info

Publication number
MX2023011498A
MX2023011498A MX2023011498A MX2023011498A MX2023011498A MX 2023011498 A MX2023011498 A MX 2023011498A MX 2023011498 A MX2023011498 A MX 2023011498A MX 2023011498 A MX2023011498 A MX 2023011498A MX 2023011498 A MX2023011498 A MX 2023011498A
Authority
MX
Mexico
Prior art keywords
lidocaine
wipes containing
containing nifedipine
nifedipine
topical
Prior art date
Application number
MX2023011498A
Other languages
English (en)
Spanish (es)
Inventor
Robbie Schwenker
Matthew Stahl
Original Assignee
Steel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steel Therapeutics Inc filed Critical Steel Therapeutics Inc
Publication of MX2023011498A publication Critical patent/MX2023011498A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023011498A 2021-04-01 2022-04-01 Toallita topica que contiene nifedipina y lidocaina. MX2023011498A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163169768P 2021-04-01 2021-04-01
PCT/US2022/023130 WO2022212892A1 (en) 2021-04-01 2022-04-01 Topical wipe containing nifedipine and lidocaine

Publications (1)

Publication Number Publication Date
MX2023011498A true MX2023011498A (es) 2024-01-17

Family

ID=83456873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011498A MX2023011498A (es) 2021-04-01 2022-04-01 Toallita topica que contiene nifedipina y lidocaina.

Country Status (8)

Country Link
US (1) US20240156756A1 (enExample)
EP (1) EP4312984A4 (enExample)
JP (1) JP2024512791A (enExample)
CN (1) CN117377461A (enExample)
AU (1) AU2022252406A1 (enExample)
CA (1) CA3213764A1 (enExample)
MX (1) MX2023011498A (enExample)
WO (1) WO2022212892A1 (enExample)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04124128A (ja) * 1990-09-13 1992-04-24 Lion Corp 肛門部疾患治療用貼付剤
JP3012732U (ja) * 1994-12-20 1995-06-27 茂郎 槇島 痔治療の薬剤保持部材
JP2001170159A (ja) * 1999-12-19 2001-06-26 Alcare Co Ltd 緩衝能を有する接皮部材
US20040167479A1 (en) * 2003-02-20 2004-08-26 The Procter & Gamble Company Hemorrhoid treatment pad
US8377459B2 (en) * 2003-07-09 2013-02-19 The Procter & Gamble Company Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin
WO2014140925A2 (en) * 2013-03-10 2014-09-18 Peritech Pharma Ltd. Topical compositions and methods of treatment of topical disorders
DK3220924T3 (da) * 2014-11-17 2022-01-03 Rev Pharma Corp Lægemiddel til topisk anvendelse til hud- og slimhindeskader i forbindelse med epidermolysis bullosa
WO2016118040A1 (ru) * 2015-01-21 2016-07-28 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий
IT201800002413A1 (it) * 2018-02-05 2019-08-05 Carmine Antropoli "composizione a base di nifedipina per uso nel trattamento delle ragadi anali e proctalgie"
WO2020176004A1 (ru) * 2019-02-25 2020-09-03 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Гель для ректального и наружного применения

Also Published As

Publication number Publication date
CA3213764A1 (en) 2022-10-06
JP2024512791A (ja) 2024-03-19
AU2022252406A1 (en) 2023-11-02
EP4312984A4 (en) 2025-02-19
WO2022212892A8 (en) 2023-11-16
EP4312984A1 (en) 2024-02-07
CN117377461A (zh) 2024-01-09
WO2022212892A1 (en) 2022-10-06
US20240156756A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
JOP20220008A1 (ar) مثبطات parp1
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
JOP20230073A1 (ar) بنزاميدات مستبدلة مع 3،1- ثيازول-2- يل
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
MX2020006664A (es) Composiciones liquidas de suministro.
UY37201A (es) Nuevos derivados de pirazolopirimidina
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
CL2008003405A1 (es) Compuestos derivados de tienopiridina, inhibidores de la enzima integrasa del vih; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion por vih.
EP2513343A4 (en) METHOD AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
CO2021008816A2 (es) Moduladores de trex1
MX2022008478A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CO2022000266A2 (es) Inhibidores de enzimas
MX2017009482A (es) Formulación farmacéutica.
CO2022000270A2 (es) Inhibidores de enzimas
ECSP23053033A (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
MX2023011498A (es) Toallita topica que contiene nifedipina y lidocaina.